Pharma segment boosts sales and profit at Gerresheimer

Seeks further expansion in emerging markets

Uwe Roehrhoff: We achieved all our targets in 2012

Gerresheimer, a German manufacturer of glass and plastic packaging, reports a significant growth in revenue and profit for 2012, particularly in the pharma segment.

Total revenue increased by 9.8% at constant exchange rates to w1.2bn, with net income rising by 22.2% to €66.5m.

Uwe Röhrhoff, CEO of Gerresheimer, said: ‘We achieved all our targets in 2012. We recorded another year of strong growth in our business activities with the pharmaceutical sector, which once again proved to be relatively immune to cyclical effects. We are investing heavily in expanding our production capacity for medical devices such as prefilled glass syringes, insulin pens and inhalers. We are also focusing on the fast-growing emerging markets, especially in China, Brazil and India. In 2012 we succeeded in expanding our position in India in particular with the acquisition of two companies there.’

In particular Gerresheimer achieved strong growth in the pharma segment coupled with good revenue results in the cosmetic glass business and the life science research segment.

Gerresheimer invested €118.9m in the 2012 financial year (up from €86.2m in 2011) to expand its production capacity for medical devices such as prefilled glass syringes, insulin pens and asthma inhalers, in Germany, Czech Republic and elsewhere.

The company is also focusing on growth in emerging markets and in April 2012 acquired Neutral Glass, one of India’s leading manufacturers of pharmaceutical vials. This was followed in December by the acquisition of the Indian company Triveni, the regional market leader for plastic pharmaceutical packaging and closures.

Gerresheimer says it plans to achieve organic growth and growth through acquisitions in the future.

The company is expecting growth in revenues at constant exchange rates of 5–6% for 2013.

Companies